18 November 2026
Genus plc
(“Genus” or the “Group”)
Board Change: Non-Executive Director Appointment
Genus (LSE: GNS), a leading global animal genetics company, is pleased to announce the appointment of Sharmila Nebhrajani to the Board as a Non-Executive Director, with effect from 1 January 2027.
Ms Nebhrajani is a Chartered Accountant with extensive experience in public sector, commercial, government and non-profit organisations across a wide range of sectors, having worked in senior roles in public health and medical research, working with government, medical charities and pharmaceutical industry partners, and latterly in government, convening international policy dialogue with governments, multi-lateral agencies, NGOs, senior policy makers and academics, on key global policy issues. Her appointment follows an extensive search process using an external search agency.
Ms Nebhrajani has a MA in Physiological Sciences from Oxford University and is currently a non-executive director and remuneration committee chair of Severn Trent plc, non-executive director and remuneration committee chair of ITV plc, senior independent director and audit committee chair of Halma plc, non-executive director of Essentra plc and Chair of the National Institute for Health and Care Excellence. She was previously a non-executive director of Coutts & Co.
Commenting on the appointment, Iain Ferguson, Chair of Genus, said:
“We are delighted to welcome Shar to the Board. Shar is a highly experienced non-executive director and audit committee chair, and brings a broad range of commercial, strategic and scientific experience and knowledge.”
For further information please contact:
Genus plc Tel: +44 (0)1256 345 970
Iain Ferguson, Chair
Jorgen Kokke, Chief Executive Officer
|
Tavistock Tel: +44 (0)20 7920 3150
|
|
|
Nick Dibden / Katie Hopkins
|
|
About Genus
Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Regulatory Notes
Details of any payments to be made to Sharmila Nebhrajani will be disclosed in full in the Company’s 2027 Directors’ Remuneration Report. Any such terms will be consistent with the Company's approved Directors’ Remuneration Policy.
This announcement is made in accordance with Listing Rule 6.4.6R. There are no matters to be disclosed in connection with Listing Rule 6.4.8R (2) – (6). The person responsible for making this announcement on behalf of the Group is Lucie Grant (General Counsel and Company Secretary).